

## **Important notice**



The material in this presentation has been prepared by Chrysos Corporation Limited (ASX: C79) ("Chrysos" or the "Group") and is general background information about Chrysos' current activities as at the date of this presentation. The information is given in summary form and does not purport to be complete. It is intended to be read by a professional analyst audience in conjunction with the Company's other announcements to ASX. Information in this presentation, including forecast financial information, should not be considered advice or a recommendation to current shareholders, investors or potential investors, in relation to holding, purchasing or selling securities in the Company, and does not take into account the investment objectives, financial situation or needs of any particular shareholder or investor. No representation or warranty, express or implied, is made as to the accuracy, reliability, adequacy or completeness of the information contained in this presentation.

#### Forward-looking statements

This presentation may contain statements that are, or may be deemed to be, forward-looking statements, for example statements that use words such as "may", "will", "would", "could", "expects", "intends", "anticipates", and other similar words that involve risks and uncertainties. You should not place undue reliance on such forward-looking statements. These statements are based on an assessment of present economic and operating conditions and on a number of best estimate assumptions regarding future events and actions that, at the date of this document, are expected to take place. No person who has made any forward-looking statements in this document has any intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this document, other than to the extent required by law. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company.

This presentation also contains references to certain intentions, expectations and plans of the Company. These intentions, expectations and plans may or may not be achieved. They are based on certain assumptions which may not be met or on which views may differ.


This presentation may contain information that has been derived from publicly available sources that have not been independent verified. No representation or warranty, express or implied, is made as to the accuracy, reliability, adequacy or completeness of this information.

Past performance information in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance

To the maximum extent permitted by law, Chrysos, its subsidiaries and their respective officers, employees, agents and consultants, and any other person involved in the preparation of this presentation, disclaim all liability and responsibility, including, without limitation, any liability arising out of fault or negligence, for any direct or indirect loss which may arise from or be suffered through use or reliance on anything contained in, or omitted from, this presentation.




## PhotonAssay<sup>™</sup> sample volumes



Continued conversion to PhotonAssay<sup>™</sup> and industry activity driving samples

#### YTD PhotonAssay™ Samples Analysed




#### **Activity Commentary**

- Sustained PhotonAssay™ demand with volumes approaching 1,000,000 samples per month
- Increased monthly throughput with growth consistently between +50-100% YoY
- Industry outlook remains positive supported by a strong gold price, exploration activity and production outlook

#### **Unaudited Revenue**


- YTD revenue of \$28.9m¹, comprising \$21.2m MMAP and \$7.6m AAC
- Additional assay charges (AAC) now represent 26.4% of revenue, up from 15.3% in FY25
- Record sample volumes remain a key revenue driver

## **Executing on our global PhotonAssay™ roll out**



Strengthening relationships with key miners and laboratories

#### **41** Units Deployed



#### YTD Activity (as at 24<sup>th</sup> Nov 2025)

- 41 PhotonAssay™ Units operating:
  - Two units deployed in FY26
    - Second at Thunder Bay, Ontario for ALS
    - Pantoro's Norseman gold mine in WA with Intertek
    - MSA Ghana unit at end of lease and will be redeployed
- Two units currently being deployed
  - SGS, Perth, deploying the new "XN" generation unit
  - ALS, Perth, deploying its 7<sup>th</sup> unit in WA
- Two new lease agreements
  - ALS. Perth
  - Acrux Gold, Scotland
- Four upcoming installations, highlighting strong global demand and continued diversified customer growth
  - Newmont's Ahafo Mine, Ghana
  - First unit for Bureau Veritas in Chile
  - MSA unit in Newfoundland, Canada
  - Allied Gold's Sadiola mine, West Africa
- MoU signed with Allied Gold for adoption of PhotonAssay™, with two units to be deployed directly to its sites, and the remainder of samples to be processed through PhotonAssay hub laboratories

PhotonAssay<sup>™</sup> units on four continents in key mining hubs

## **Financial highlights**



**Record sample volumes continue to underpin revenue** 



#### **FY26 Guidance**


- Reiterated FY26 guidance<sup>1</sup> of:
  - FY26 Total Revenue range of \$80m to \$90m
  - FY26 EBITDA range of \$20m to \$27m

#### **Cash & Debt Position**

- Cash on hand \$26.7m<sup>2</sup>
- \$95m debt facility from CBA, of which \$46.0m<sup>2</sup> has been drawn
- Well-funded to support PhotonAssay™ unit growth



## **Research and Development Drivers**



#### Advancing capability to enable sustainable growth

#### **Quality and Resilience**

**Supply chain** resilience ensures providers are available for all critical components which cannot be produced in-house. Chrysos maintains practical ownership of its IP and the ability to freely build and support its equipment.


**Performance** delivery means Chrysos units continuously provide high-quality results that meet or exceed customer expectations. Data are fit-for-purpose and support miners meeting JORC or NI-43101 reporting obligations.

**Reliability** improvements mean instruments are always available when needed. Spare parts, maintenance and support staff requirements are minimised.

Ease-of-use units are straightforward to operate with minimal training. As far as possible, the quality of results should not depend on operator skill.

Continuing to develop our ability to independently manufacture, install and support units is critical to Chrysos' long-term growth





New opportunities must meet thresholds of scale. industry need and Chrysos' ability to deliver a unique solution


#### **Broaden the Offering**

New PhotonAssay<sup>™</sup> services allow more to be done with existing units, often with no more than a software upgrade. New services include assaying a wider range of elements, or existing elements in different materials or matrices.


**New technologies** expand our analysis capabilities beyond PhotonAssay™, adding options for new elements or other material properties such as mineralogy or density. Preferred technologies build on Chrysos' strength of bulk analysis of large, unprepared samples.

Expanding up- and down-stream makes PhotonAssay™ a more compelling offering by reducing bottlenecks in sample preparation, data quality control and reporting. Provision of a more end-to-end service is especially relevant for mine-site installations.

## **Expanding Footprint in the Mining Data Chain**



#### Delivering faster and more reliable analysis results for more materials



Opportunities to integrate preparation and PhotonAssay™ for smarter sampling decisions.

Lab manually dries, crushes and splits samples into jars. These are then scanned and run through PhotonAssay™ units for Au, Ag and/or Cu. Automated QC is performed and data quality reviewed. Batch results are reported to the lab or client laboratory information management system (LIMS).


Aggregation of PhotonAssay™ and sample metadata into one online portal. Enhanced quality control and reporting tools provide better transparency of data provenance for end-users. Opportunities to prioritise urgent samples and push results directly to specific endpoints, e.g. plant or mine control systems.



















COLLECTION

**TRANSPORT** 

**PREPARATION** 

**ASSAY** 

QC REPORTING


ACTION

Generate **additional revenue** from existing deployed PhotonAssay™ unit base, either from better utilisation or simultaneous services.



New elements etc, measured directly on existing PhotonAssay™ sample jars Overcome resistance where the client needs additional services beyond Au, Ag and Cu. Reduce the need for additional laboratory staff, space or equipment.

## PhotonAssay™ - The Next Generation



#### Improving quality, resilience and performance

#### **41** Units Deployed

(at 24 November 2025)



#### Generation 2 – parallel supply chains

**XC units** target the North American market including the US, Canada and Mexico. They include US-made X-ray sources and detectors and Australian-sourced automation and shielding components. Other components are wholly designed and sourced by the Chrysos team.

XN units are manufactured in partnership with our existing supplier, Nuctech Technology Ltd. They include upgraded versions of the X-ray source, a wholly new automation system and a smaller footprint.


**Robotic automation** used in both systems is a substantial upgrade on the Gen-1 units, designed for higher reliability and availability. It offers more flexible operation and higher sample throughput.

Ease-of-use is improved by internalising several operator functions, including sample mass and fill registration, instrument calibration, standard insertion for performance monitoring and handling of naturally radioactive samples.

## PhotonAssay™ - XC




#### The Aussie contender




Automation redesign undertaken in partnership with Australian companies SAGE and Automation Innovation. High-performance robot executes majority of sample handling, providing flexibility to reprogram operations and add additional analysis stages. Installed as an upgrade to ITK1 unit and operating successfully in Perth since May 2025. Throughput increased to 83-84 jars per hour.

X-ray source (accelerator) developed for Chrysos by the US company Accelerad. Modular design with many key components available 'off the shelf' from commercial vendors. Training provided for Chrysos staff to install and maintain accelerators around the world.

**Shielding** sees supply chain decoupled from Chinese manufacturers.



## PhotonAssay™ - XN




#### **Continuing the Nuctech partnership**

Shared automation design with XC, building on the successful operating experience with the first prototype. Manufacture will be transferred to China for more efficient integration with Nuctech's supply chain.

Cabins have been redesigned to significantly reduce footprint and the required facility height, with the aim of making it easier to find existing buildings to accommodate new units.


Shielding redesigned for easier, faster and safer installation. Splitting accelerator cabin into two parts allows for shipping and onsite setup without removing heavy shielding blocks.








## **RAFT - Rapid Analysis of Fill & Transmission**




#### Improving ease-of-use and data quality

Jar fill level and gamma-ray transmission are important parameters needed for accurate analysis of gold and other elements

- Several parameters, including sample mass, jar fill level and how easily radiation passes through the sample material ('gamma-ray transmission'), are inputs into the calibration algorithm
- The jar fill level is currently measured by the operator using an optical camera system. This requires careful attenuation and can be affected by dusty or dirty jars and particularly light or dark sample materials
- Accurate knowledge of gamma-ray transmission is particularly important for certain elements. This factor currently dominates the analysis precision for silver, for example.
- The RAFT project overcomes both these limitations, determining the jar fill using an X-ray scan and directly measuring radiation absorption using a small radioisotope source
- RAFT will be included as standard in XC and XN units, and has been designed as a retrofittable upgrade for existing Generation 1 units
- Result: easier process for users, 3-4× better jar fill and gamma-ray transmission measurements and more accurate assay results





## **Broadening the Offering**



Moving beyond gold, silver and copper; making life easier on-site

#### Doing more with standard PhotonAssay™

- PhotonAssay<sup>™</sup> systems were always designed to be inherently software-upgradeable
- Changing the operating conditions of the X-ray source allows a wide range of elements to be excited
- The high-resolution detector system allows emissions from these elements to be distinguished and counted
- Upgrading the analysis software and internal corrections tables allows new elements to be assayed and reported

#### Modifying PhotonAssay<sup>™</sup> for new elements

- Neutron activation analysis (NAA) is a powerful complement to PhotonAssay™
- NAA enables the analysis of many elements that are not accessible to PhotonAssay™
- Analysis can potentially be performed using existing X-ray source and detector systems
- Concepts for a combined PhotonAssay™/NAA system are under development


#### New assay technologies

- Take advantage on work already done to obtain, label and prepare samples for PhotonAssay™
- Focus on technologies that provide complementary analysis capabilities
- Measurements performed on bulk, minimally prepared samples in existing jars
- Current focus on X-ray fluorescence (XRF) analysis, already widely used and accepted in minerals industry
- Additional technologies planned in the future

#### Automated sample preparation


- With labour savings realised from elimination of fire-assay, sample preparation is major driver of onsite manpower requirements
- Sample preparation requirements for PhotonAssay™ are a good match for emerging automated technologies


## New elements with standard PhotonAssay™



#### **Unlocking further market opportunities**

- Measurement via PhotonAssay™ requires an element to have a suitable activation reaction with a short half-life and distinctive emission signature
- About half the elements in the periodic table meet these basic requirements
- Changing the energy and duration of the X-ray activation phase can target specific elements or element combinations
- Two applications under active development are analysis of antimony (Sb) and uranium (U)
- Applications must always meet basic requirements of market scale, industry need and PhotonAssay™ performance








Stibnite, a major ore source of antimony<sup>1</sup>



Uraninite, a significant ore source of uranium<sup>1</sup>

## **Neutron analysis using PhotonAssay™ units**



#### **Broadening our element coverage**

- **Neutrons** are emitted as a by-product from the X-ray source in a PhotonAssay<sup>™</sup> unit
- Current instrument design minimises their production, but there are opportunities to modify the source design to rapidly 'tune' neutron production
- Computer modelling is being used to optimise instrument design and calculate likely performance for different elements
- Experimental testing planned for coming calendar year
- **Applications** to many critical, commodity and penalty elements



ACT

Neutrons are one of the constituents of atomic nuclei, the other being protons. Being uncharged, neutrons penetrate solid samples easily and are well suited to bulk analysis

#### Critical minerals

- Scandium
- Vanadium
- Manganese
- Antimony

#### Penalty/deleterious elements

- Fluorine
- Arsenic
- Sulphur


#### **Rock-forming** elements

- Silicon
- Aluminium
- Calcium
- Iron etc

#### Commodity elements


- Aluminium
- **Titanium**
- Tin
- Rare earths


## **New technologies – X-ray Fluorescence**





#### Fast, low-cost supplement to PhotonAssay™

- Widely deployed technology for multi-element analysis
- Accurate, quantitative lab applications require careful and extensive sample preparation typically fusion due to significant matrix and particle size effects
- 'Low-prep' approaches such as portable XRF (pXRF) typically provide only semi-quantitative data, but there is growing interest in performing semi-automated pXRF as a fast, low-cost adjunct analysis in laboratory settings
- Chrysos is exploring targeted XRF performed directly on samples inside PhotonAssay™ jars. The team has significant R&D experience in on-stream XRF analysis of mineral slurries and similarly 'unprepared' materials
- Equipment would be installed inside PhotonAssay™ units and operate in parallel without reducing overall sample throughput or analysis time
- Opportunities to combine PhotonAssay<sup>™</sup> and XRF data to improve calibration performance











## **Automated Sample Preparation**



#### Towards a fully automated on-site laboratory

- Several industrial automation specialist providers have developed automated sample preparation solutions specifically targeted at PhotonAssay™
- Typically, these include manual loading of sample bags by operators, followed by automated crushing, splitting, jarring and weighing
- Samples can then be automatically conveyed to PhotonAssay™ unit for analysis and reporting
- Parallel installations are currently planned or underway at client sites in North America and Australia

Action	Fire-assay	PhotonAssay™
Sample receipt	2.2	11
Sample prep	1111	1111
Assay	11111	***
Lab finish	11111	
Admin/QC	111	***



Staffing for lab, 1500 samples/day (manual prep)

# Long-term IP strength is about momentum, not position



## Thank you

For more information, please visit **chrysoscorp.com** or contact us at **investors@chrysoscorp.com** 

